Abstract: The present invention provides iron oxide magnetic particles containing iron oxide and MXn, wherein M as a transition metal containing electrons in a 5d orbital on the periodic table includes one or more selected from the group consisting of Hf, Ta, W, Re, Os, Ir, Pt, Au, and Hg, X includes one or more selected from the group consisting of F, Cl, Br, and I, and n is an integer of 1 to 6.

Abstract: The present invention provides iron oxide magnetic particles containing iron oxide and MXn, wherein M as a transition metal containing electrons in a 6p orbital on the periodic table includes one or more selected from the group consisting of Tl, Pb, Bi, and Po, X includes one or more selected from the group consisting of F, Cl, Br, and I, and n is an integer of 1 to 6.

Abstract: The present invention provides iron oxide magnetic particles including an iron oxide and MXn, wherein M includes one or more selected from the group consisting of Cu, Sn, Pb, Mn, Ir, Pt, Rh, Re, Ag, Au, Pd, and Os, X includes one or more selected from the group consisting of F, Cl, Br, and I, and n is an integer of 1 to 6.

Abstract: The present invention provides a method for preparing iron oxide magnetic particles and iron oxide magnetic particles prepared thereby, wherein the method includes (a) synthesizing a complex by reacting iron and one or more compounds selected from the group consisting of an aliphatic hydrocarbonate having 4 to 25 carbon atoms and an amine compound, (b) synthesizing an iron oxide crystal nucleus by mixing the complex with a mixture of an unsaturated aliphatic hydrocarbon-based compound having 4 to 25 carbon atoms and an ether-based compound, and (c) forming a shell by mixing the iron oxide crystal nucleus and an MXn compound with a mixture of an unsaturated aliphatic hydrocarbon-based compound having 4 to 25 carbon atoms and an ether-based compound, wherein M is a heavy atom element, X is a halogen element, and n is an integer of 1 to 6.

Abstract: Disclosed is a composition comprising iron oxide magnetic particles. The composition is delivered to a liver in a hepatocyte-specific manner to minimize damage to other organs, and is safely excreted from a body within a few weeks. Further, the particles have excellent hepatocyte targeting ability, and thus are used as a liver cancer treatment agent and a hepatocyte targeting carrier.